Close
Company Search
Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

4basebio Plc (4BB) Share Price

Price 435.00p on 14-05-2026 at 16:30:01
Change 0.00p 0%
Buy 450.00p
Sell 420.00p
Add to Watchlist
Add to Portfolio
Add to Quickpicks
Last Trade: Sell 21.00 at 420.00p
Day's Volume: 79
Last Close: 435.00p
Open: 435.00p
ISIN: GB00BMCLYF79
Day's Range 435.00p - 435.00p
52wk Range: 425.00p - 1,125.00p
Market Capitalisation: £67.36m
VWAP: 441.94177p
Shares in Issue: 15.48m

Sector: Medicine and Biotech

Listed In: FTSE AIM All-Share,

4basebio Plc (4BB) Latest Trades

Buy/Sell Volume Trade Prc Trade Type Trade Time
Sell* 21 420.00p Ordinary
 13:22:12 - 14-May-26
Buy* 22 449.70p Ordinary
 12:25:35 - 14-May-26
Buy* 6 450.00p Ordinary
 08:00:05 - 14-May-26
Unknown* 0 420.00p SI Trade
 08:00:05 - 14-May-26
Buy* 3 450.00p SI Trade
 08:00:05 - 14-May-26
Buy* 2 450.00p SI Trade
 08:00:05 - 14-May-26
Unknown* 0 450.00p SI Trade
 08:00:05 - 14-May-26
Buy* 25 450.00p Ordinary
 08:00:00 - 14-May-26
Sell* 74 420.00p Ordinary
 15:19:46 - 13-May-26
Buy* 6 450.00p Ordinary
 12:49:50 - 13-May-26
See more 4basebio Plc trades

4basebio Plc (4BB) Share Price History

Time period:
to
Date Open High Low Close Volume
14th May 2026 (Thu) 435.00 435.00 435.00 435.00 79
13th May 2026 (Wed) 435.00 435.00 435.00 435.00 393
12th May 2026 (Tue) 455.00 455.00 425.00 435.00 8,285
11th May 2026 (Mon) 455.00 455.00 455.00 455.00 2,052
8th May 2026 (Fri) 455.00 455.00 455.00 455.00 397
7th May 2026 (Thu) 484.00 460.00 460.00 460.00 2,165
6th May 2026 (Wed) 485.00 488.00 484.00 484.00 3,114
5th May 2026 (Tue) 505.00 505.00 485.00 485.00 2,166
4th May 2026 (Mon) 505.00 505.00 505.00 505.00 0
1st May 2026 (Fri) 505.00 505.00 505.00 505.00 38
30th Apr 2026 (Thu) 505.00 505.00 505.00 505.00 2
29th Apr 2026 (Wed) 505.00 505.00 505.00 505.00 4,198
28th Apr 2026 (Tue) 505.00 530.00 505.00 505.00 4,161
27th Apr 2026 (Mon) 505.00 505.00 505.00 505.00 1,114
24th Apr 2026 (Fri) 505.00 505.00 505.00 505.00 13
23rd Apr 2026 (Thu) 505.00 505.00 505.00 505.00 1,314
22nd Apr 2026 (Wed) 505.00 505.00 505.00 505.00 1
21st Apr 2026 (Tue) 505.00 505.00 505.00 505.00 265
20th Apr 2026 (Mon) 505.00 505.00 505.00 505.00 804
17th Apr 2026 (Fri) 505.00 505.00 505.00 505.00 696
16th Apr 2026 (Thu) 505.00 505.00 505.00 505.00 4
15th Apr 2026 (Wed) 505.00 505.00 505.00 505.00 667
See more 4basebio Plc price history

4basebio Plc (4BB) Regulatory News

Date Source Headline
14th May 2026 7:00 am PRN Appointment of Chief Financial Officer and Board Changes
11th May 2026 7:00 am PRN 4basebio Launches Enzymatic ssDNA Platform
31st Mar 2026 7:00 am PRN Lease of Manufacturing Facility
12th Mar 2026 7:00 am PRN Appointment of COO
3rd Mar 2026 7:00 am PRN Appointment of CCO
16th Feb 2026 7:00 am PRN Director Dealing
11th Feb 2026 3:58 pm PRN Director Dealing
10th Feb 2026 7:00 am PRN Leadership Changes
27th Oct 2025 7:00 am PRN Synthetic opDNA® utilised in Phase I/II US clinical trials
10th Oct 2025 11:30 am PRN Result of Extraordinary General Meeting
See more 4basebio Plc regulatory news

4basebio Plc (4BB) Share News

IN BRIEF: 4basebio appoints Richard Bungay chief financial officer

14th May 2026 20:04

4basebio PLC - Cambridge, England-based life sciences company - Appoints Richard Bungay as chief financial officer. Bungay will assume the role from July 2026, succeeding David Roth. Bungay previously served as chief executive officer and chief financial officer of Diurnal Group PLC, the Cardiff, Wales-based pharma company, and he currently serves as a non-executive director of Chroma Therapeutics Ltd, the Birmingham, England-based biotechnology company. Amy Walker, 4basebio chief executive officer, says: "Richard has a long and accomplished career in the industry... we are thrilled that he has decided to join 4basebio." Read More

IN BRIEF: 4basebio launches high‑capacity single‑stranded DNA platform

12th May 2026 01:06

4basebio PLC - Cambridge, England-based life sciences company - Launches high-capacity single stranded-DNA for therapeutics. The company says the platform, ssDNA, will "accelerate the development of safer, more precise genetic therapies by targeting gene editing, advanced cell engineering and innovative nucleic acid-based medicines." 4basebio will showcase its proprietary advancements at the American Society for Gene & Cell Therapy Annual Meeting in Boston on May 14, 2026. Read More

4BaseBio expands facilities to support growing synthetic DNA demand

1st Apr 2026 08:23

(Alliance News) - 4Basebio PLC on Tuesday said it is expanding to a new innovation hub and manufacturing facility at its headquarters in Cambridge, England to support growing demand. Read More

IN BRIEF: 4basebio appoints Scott Lorimer as chief operating officer

12th Mar 2026 14:31

4basebio PLC - Cambridge, England-based life sciences company - Appoints Scott Lorimer as chief operating officer, with immediate effect. This follows the appointment last week of Christine Wolosin as chief commercial officer, and of Amy Walker last month as chief executive. 4basebio says he will be responsible for scaling its synthetic DNA platform to serve its client base in the cell and gene therapy, mRNA, and vaccine markets. He will also oversee manufacturing operations, quality and regulatory compliance, process development, and supply chain and facility management. Read More

4basebio promotes Christine Wolosin to chief commercial officer

9th Mar 2026 06:58

(Alliance News) - 4basebio PLC on Tuesday announced the promotion of Business Development Vice President Christine Wolosin to chief commercial officer, following the appointment of Amy Walker to chief executive last month. Read More

See more 4basebio Plc news
FTSE 100 Latest
Value10,372.93
Change47.58

Login to your account

Forgot Password?

Not Registered